Nuo Therapeutics, Inc. (AURX)
AURX is quoted over the counter, not listed on an exchange. Nuo Therapeutics, Inc. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-13.
Profile
| Field | Value |
|---|---|
| Ticker | AURX, quoted over the counter |
| SEC CIK | 0001091596 |
| OTC Markets tier | OTCQB (price source, 2026-11-13) |
| SEC industry code | Surgical & Medical Instruments & Apparatus |
| Business address | Houston, TX |
| Incorporated in | DE |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "As such, we believe that substantial doubt about our ability to continue as a going concern exists." | 10-Q 2026-11-13 |
| Cash and burn | $449K cash; operating cash flow -$537K a quarter. | Report 2026-06-30 |
| Shares outstanding | 48,585,593 (2026-11-12); 48,077,745 a year earlier; 42,316,516 three years earlier. | Cover page 2026-11-12 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | MaloneBailey, LLP, Houston, Texas, United States | PCAOB Form AP 2026-04-01 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $10K, sold $300K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $1.8M | -$278K | -$236K | $449K | No debt tags | $5.2M | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | $1.3M | -$618K | -$784K | $264K | No debt tags | $4.1M | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | $1.1M | -$578K | -$423K | $549K | No debt tags | $3.3M | 10-K 2026-03-30 |
| Q3 2025 2025-09-30 | $1.0M | -$538K | -$707K | $515K | No debt tags | $2.6M | 10-Q 2025-10-30 |
| Q2 2025 2025-06-30 | $700K | -$650K | $262K | $316K | No debt tags | $2.0M | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | $484K | -$746K | $2K | $56K | No debt tags | $1.6M | 10-Q 2026-05-14 |
| Q4 2024 2024-12-31 | $395K | -$497K | -$491K | $284K | No debt tags | $1.4M | 10-K 2026-03-30 |
| Q3 2024 2024-09-30 | $371K | -$578K | -$487K | $684K | No debt tags | $1.2M | 10-Q 2025-10-30 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2025-05-01 |
| Latest annual report | 10-K | 2026-03-30 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report | 8-K | 2026-10-06 |
| Latest proxy | DEFA14A | 2025-10-30 |
Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier